共 160 条
[1]
Awan AA(2019)Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease Nephrol Dial Transplant 142 44-50
[2]
Walther CP(2019)Iron deficiency anemia in chronic kidney disease Acta Haematol 8 523-9098
[3]
Richardson PA(2019)Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and in CKD patients: a two cohorts study J Clin Med 233 9087-572
[4]
Shah M(2018)The role of hypoxia-inducible factor-2 alpha in angiogenesis J Cell Physiol 79 563-1010
[5]
Winkelmayer WC(2019)Roxadustat: first global approval Drugs 381 1001-1386
[6]
Navaneethan SD(2019)Roxadustat for anemia in patients with kidney disease not receiving dialysis N Engl J Med 32 1373-1454
[7]
Gafter-Gvili A(2017)Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China Nephrol Dial Transplant 36 1438-1673
[8]
Schechter A(2019)Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2 randomized, double-blind, placebo-controlled trial Adv Therapy 30 1665-388
[9]
Rozen-Zvi B(2015)Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients Nephrol Dial Transplant 45 380-1122
[10]
Spoto B(2017)Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease Am J Nephrol 90 1115-871